9. BARTER TRANSACTION
During 2012, we entered into a barter transaction, exchanging laboratory capital assets with a zero net book value for barter credits on future apatorsen preclinical research services. The credits were recorded at the fair value of the laboratory capital assets exchanged, in accordance with ASC 845, “Nonmonetary Transactions” resulting in other income of $0.2 million, which was recorded in our Consolidated Statement of Loss, in 2012. As of December 31, 2013 all the barter credits had been utilized in exchange for preclinical research services related to apatorsen.